TenX Keane Acquisition Ordinary Share (TENK)

NASDAQ: TENK · IEX Real-Time Price · USD
11.44
+0.01 (0.09%)
At close: Jul 19, 2024, 12:00 AM
11.41
-0.03 (-0.26%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Market Cap 76.11M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.65M
EPS (ttm) 0.27
PE Ratio 42.37
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,666
Open 11.43
Previous Close 11.43
Day's Range 11.35 - 11.49
52-Week Range 10.63 - 12.03
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About TENK

TenX Keane Acquisition does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. TenX Keane Acquisition was incorporated in 2021 and is based in New York, New York. [Read more]

Industry Shell Companies
Sector Financials
IPO Date Oct 14, 2022
Country United States
Stock Exchange NASDAQ
Ticker Symbol TENK
Full Company Profile

Financial Performance

Financial Statements

News

TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the “Company”), announced today that if the proposal to amend the Company's Amended and Restated Me...

6 months ago - GlobeNewsWire

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceutica...

Other symbols: CTXR
7 months ago - PRNewsWire

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transact...

Other symbols: CTXR
9 months ago - PRNewsWire

TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination

New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its initial ...

9 months ago - GlobeNewsWire

TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022

New York, NY, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (Nasdaq: TENKU), a newly incorporated blank check company, today announced that, commencing on December 8, 2022, ...

1 year ago - GlobeNewsWire

TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter's Over-Allotment Option

New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU) (the “Company”), a newly incorporated blank check company incorporated as a Cayman Islands exempted company formed for...

1 year ago - GlobeNewsWire

TenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering

New York, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”), a newly incorporated blank check company incorporated as a Cayman Islands exempted company formed for the purpose of...

1 year ago - GlobeNewsWire